

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR ATTORNEY DOCKET NO		CONFIRMATION NO.	
10/702,096	11/05/2003	Stephen D. Kuslich	C364.104.101(19478-00005) 6813		
	7590 01/29/200 THUENTE, SKAAR &	EXAMINER			
4800 IDS CENT		STEWART, ALVIN J			
80 SOUTH 8TH MINNEAPOLIS	STREET S, MN 55402-2100	ART UNIT	PAPER NUMBER		
·			3738		
				·	
SHORTENED STATUTORY	Y PERIOD OF RESPONSE	. MAIL DATE	DELIVERY MODE		
3 MON	NTHS	DADED			

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Ap	pplication No. Applicant(s)					
Office Andien Oursenance		10	0/702,096		KUSLICH, STEPHEN D.			
Office Action Summary			xaminer		Art Unit			
		Alv	lvin J. Stewa	rt	3738			
Period fo	The MAILING DATE of this communi r Reply	cation appears	rs on the co	ver sheet with the c	orrespondence ad	ldress		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
1\⊠	Responsive to communication(s) file	d on 06 April :	2006					
•	Responsive to communication(s) filed on <u>06 April 2006</u> . This action is FINAL . 2b)⊠ This action is non-final.							
		•—			secution as to the	e merits is		
٥/١	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims								
4) 🖂	Claim(s) 1,2,4,8,16,17,19,23-31 and	33 is/are pen	nding in the	application.				
	4a) Of the above claim(s) is/are withdrawn from consideration.							
	5) Claim(s) is/are allowed.							
•	6) Claim(s) 1,2,4,8,16,17,19,23-31 and 33 is/are rejected.							
•	Claim(s) is/are objected to.	-						
8)	Claim(s) are subject to restric	tion and/or ele	ection requ	irement.				
Applicati	on Papers							
9)	The specification is objected to by the	e Examiner.						
	The drawing(s) filed on <u>27 Septembe</u>		: a)⊠ acce	pted or b) objec	ted to by the Exar	miner.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority (ınder 35 U.S.C. § 119			•				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) Notice 3) Infor	et(s) ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (Formation Disclosure Statement(s) (PTO-1449 or Province)		5)	Interview Summary Paper No(s)/Mail Do Notice of Informat P Other:	ate	O-152)		

Application/Control Number: 10/702,096

Art Unit: 3738

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 01/05/07 has been entered.

Response to Arguments

Applicant's arguments with respect to claims <u>1,2,4,8,16,17,19,23-31 and 33</u> have been considered but are moot in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 2, 4, 8, 16, 17, 19, 23-31 and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Belef et al US Pub. 2002/0147496 A1 in view of Pernia et al US Patent 5,634,945.

Belef et al discloses a system comprising an injection tube (14) having a diameter similar to the partially excavated cavity (96), a volume of tissue promoting material (π 61) and an insertion device coupled to the injection tube (see π 62 & 64). Regarding claims 2 and 8, see

paragraph 65. However, Belef et al does not disclose one or more strands of the tissue promoting material.

Pernia et al disclose a biological filler comprising a plurality of strands for the purpose of replacing soft tissue which is available, cost effective and not likely to suffer rejection or complications from its use (see col. 1, lines 50-56, lines 61-66; col. 2, lines 39-42, lines 61-67; and col. 3, lines 1-20).

It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the filler of the Belef et al reference with the biocompatible filler of the Pernia et al reference in order to provide a material for use as a replacement for soft tissue which is available, cost effective, and not likely to suffer rejection or complications from its use.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alvin J. Stewart whose telephone number is 571-272-4760. The examiner can normally be reached on Monday-Friday 7:00AM-5:30PM(1 Friday B-week off).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on 571-272-4754. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/702,096 Page 4

Art Unit: 3738

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A. Struct

ALVIN J. STEWART PRIMARY EXAMINER Art Unit 3738

January 18, 2007.